{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:10:54Z","timestamp":1778152254688,"version":"3.51.4"},"reference-count":41,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2026,2,7]]},"DOI":"10.1080\/14737167.2025.2603941","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:21:55Z","timestamp":1765538515000},"page":"203-210","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of second- or third-line treatment with tisotumab vedotin for metastatic or recurrent cervical cancer"],"prefix":"10.1080","volume":"26","author":[{"given":"Mar\u00eda del Pilar","family":"Brice\u00f1o-Casado","sequence":"first","affiliation":[{"name":"Hospital Universitario Puerto Real","place":["C\u00e1diz, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"S\u00e1nchez Vegas","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Hospital Universitario Nuestra Se\u00f1ora de Valme","place":["Sevilla, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio Jes\u00fas","family":"Alegre-Del-Rey","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerto Real","place":["C\u00e1diz, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5448-1370","authenticated-orcid":false,"given":"Antonio","family":"Olry de Labry Lima","sequence":"additional","affiliation":[{"name":"Instituto de Salud Carlos III (CIBERESP)","place":["Madrid, Spain"]},{"name":"Escuela Andaluza de Salud P\u00fablica","place":["Granada, Spain"]},{"name":"Instituto de Investigaci\u00f3n Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada, Universidad de Granada","place":["Granada, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"#cr-split#-e_1_3_6_3_1.1","unstructured":"Global Cancer Observatory. Statistics at a glance 2022. Top 5 most frequent cancers: number of new cases 4 471 422 [Internet]. Lyon: International Agency for Research on Cancer"},{"key":"#cr-split#-e_1_3_6_3_1.2","unstructured":"2022 [cited 2025 Mar 18]. Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/908-europe-fact-sheet.pdf"},{"key":"e_1_3_6_4_1","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM). Cancer figures in Spain [Internet]. Madrid: SEOM; 2023 [cited 2025 Mar 18]. Available from: https:\/\/seom.org\/images\/Las_cifras_del_Cancer_en_Espana_2023.pdf"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30716"},{"key":"e_1_3_6_6_1","volume-title":"NCCN guidelines version 3.2025: Cervical cancer","author":"Gaillard S","year":"2025","unstructured":"Gaillard S, Giuntoli RL II, Glaser S, et al. NCCN guidelines version 3.2025: Cervical cancer [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2025 [cited 2025 Mar 18]. Available from: https:\/\/www.nccn.org\/home\/member-"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00056-5"},{"key":"e_1_3_6_8_1","unstructured":"European Society for Medical Oncology (ESMO). ESMO-MCBS scorecards | ESMO. 2025 [cited 2025 Mar 20]. Available from: https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-solid-tumours\/esmo-mcbs-scorecards\/scorecard-299-1"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313811"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.10.008"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2025.102448"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.2094"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.012"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1917140"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e58"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2023.14.2.4"},{"key":"e_1_3_6_17_1","unstructured":"Torrej\u00f3n Cardoso R Calero Fern\u00e1ndez MR Carlos Gil AM et al. Proceso asistencial integrado c\u00e1ncer de c\u00e9rvix - Junta de Andaluc\u00eda [Internet]. 2010 [cited 2025 Mar 30]. Available from: https:\/\/www.juntadeandalucia.es\/organismos\/saludyconsumo\/areas\/calidad\/pai\/paginas\/pai-cancer-cervix.html"},{"key":"e_1_3_6_18_1","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Informe de posicionamiento terap\u00e9utico de cemiplimab (Libtayo\u00ae) en monoterapia para el tratamiento del c\u00e1ncer de cuello uterino metast\u00e1sico o recurrente y en progresi\u00f3n durante o despu\u00e9s de quimioterapia basada en platino [Internet]. Madrid: AEMPS; 2023 [cited 2025 Mar 30]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2023\/IPT-205-Cemiplimab-Libtayo.pdf"},{"key":"e_1_3_6_19_1","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Informe de posicionamiento terap\u00e9utico de pembrolizumab (Keytruda\u00ae) en combinaci\u00f3n con quimioterapia con o sin bevacizumab en el tratamiento del c\u00e1ncer de cuello uterino persistente recurrente o metast\u00e1sico. [Internet]. Madrid: AEMPS; 2024 Oct 30 [cited 2025 May 4]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2024\/IPT-315-Keytruda-pembrolizumab-QT-bevacizumab.pdf"},{"key":"e_1_3_6_20_1","unstructured":"Ministerio de Sanidad (Espa\u00f1a). Informaci\u00f3n sobre los productos incluidos en la prestaci\u00f3n farmac\u00e9utica del SNS: Nomencl\u00e1tor de facturaci\u00f3n [Internet]. [cited 2025 Oct 16]. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/nomenclator.do"},{"key":"e_1_3_6_21_1","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos (CGCOF). BOTPLUS [Internet]. [cited 2025 Mar 30]. Available from: https:\/\/botplusweb.farmaceuticos.com\/"},{"key":"e_1_3_6_22_1","unstructured":"Bolet\u00edn Oficial del Estado (BOE). BOE-A-2010\u20138228 Real Decreto-ley 8\/2010 de 20 de mayo por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. [Internet]. Madrid: BOE; 2010 May 24 [cited 2025 Mar 30]. Available from: https:\/\/www.boe.es\/buscar\/act.php?id=BOE-A-2010-8228"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112187"},{"key":"e_1_3_6_24_1","unstructured":"Bolet\u00edn Oficial de la Junta de Andaluc\u00eda (BOJA). Bolet\u00edn oficial de la junta de Andaluc\u00eda consejer\u00eda de salud y consumo [Internet]. [cited 2025 Mar 30]. Available from: https:\/\/www.juntadeandalucia.es\/eboja3.Otrasdisposiciones"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-023-00456-6"},{"key":"e_1_3_6_26_1","unstructured":"European Society for Medical Oncology (ESMO). ESMO-MCBS scorecard 507 [Internet]. [cited 2025 Oct 16]. Available from: https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-solid-tumours\/esmo-mcbs-scorecards?scorecard=507"},{"key":"e_1_3_6_27_1","unstructured":"Oncology ES for M. ESMO magnitude of clinical benefit scale | evaluation forms [Internet]. [cited 2025 Apr 6]. Available from: https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-solid-tumours\/esmo-mcbs-evaluation-forms"},{"key":"e_1_3_6_28_1","unstructured":"Ministerio de Sanidad Comit\u00e9 Asesor para la Financiaci\u00f3n de la Prestaci\u00f3n Farmac\u00e9utica del SNS (CAPF). Recomendaciones sobre los criterios y procedimiento para orientar la fijaci\u00f3n de precios y la inclusi\u00f3n y exclusi\u00f3n en la financiaci\u00f3n p\u00fablica de medicamentos en el SNS [Internet]. Versi\u00f3n 16 de junio de 2022 [cited 2025 Oct 16]. Available from: https:\/\/www.sanidad.gob.es\/areas\/farmacia\/comitesAdscritos\/prestacionFarmaceutica\/docs\/20220615_Recoms_Finales_LE2_1LE2_2_CAPF_v15.pdf"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.farma.2024.10.011"},{"key":"e_1_3_6_30_1","unstructured":"European Medicines Agency (EMA). Libtayo | European Medicines Agency (EMA) [Internet]. [cited 2025 Apr 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/libtayo"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta21260"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16670617"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aprim.2016.08.001"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1135-57272004000300001"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.15.1453"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2019.02.009"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.06.012"},{"key":"e_1_3_6_38_1","unstructured":"Vallejo-Torres L Garc\u00eda-Lorenzo B Castilla I et al. Valor monetario de un a\u00f1o de vida ajustado por calidad: estimaci\u00f3n emp\u00edrica del coste de oportunidad en el sistema nacional de salud. Ministerio de Sanidad Servicios Sociales e Igualdad. Servicio de evaluaci\u00f3n del Servicio Canario de la Salud. Informes de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias [Internet]. 2015 [citado 4 de mayo de 2025]. Available from: https:\/\/sescs.es\/wp-content\/uploads\/2015\/09\/SESCS-2015_Umbral-C.O.-AVAC.pdf?x10245"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02472-7"},{"key":"e_1_3_6_40_1","unstructured":"European Society for Medical Oncology (ESMO). ESMO-MCBS scorecard 361 [Internet]. [cited 2025 Oct 16]. Available from: https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-solid-tumours\/esmo-mcbs-scorecards?scorecard=361"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-025-00960-1"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2024.0279"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2025.2603941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:18:26Z","timestamp":1778149106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2025.2603941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,7]]}},"alternative-id":["10.1080\/14737167.2025.2603941"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2025.2603941","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}